Share-based Payment Arrangement, Expense of Senti Biosciences, Inc. from 30 Jun 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Senti Biosciences, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2021 to 30 Sep 2025.
  • Senti Biosciences, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,551,000, a 132% increase year-over-year.
  • Senti Biosciences, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $4,886,000, a 9.7% decline year-over-year.
  • Senti Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $1,755,000, a 85% decline from 2023.
  • Senti Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $11,692,000, a 25% decline from 2022.
  • Senti Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $15,562,000, a 578% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Senti Biosciences, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $4,886,000 $1,551,000 +$883,000 +132% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $4,003,000 $1,526,000 +$2,302,000 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $1,701,000 $1,204,000 -$54,000 -4.3% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $1,755,000 $605,000 -$3,657,000 -86% 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
Q3 2024 $5,412,000 $668,000 +$259,000 +63% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $5,153,000 $776,000 -$4,210,000 -123% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $9,363,000 $1,258,000 -$2,329,000 -65% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $11,692,000 $4,262,000 +$676,000 +19% 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
Q3 2023 $11,016,000 $409,000 -$1,681,000 -80% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $12,697,000 $3,434,000 -$5,791,000 -63% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $18,488,000 $3,587,000 +$2,926,000 +443% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $15,562,000 $3,586,000 01 Oct 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
Q3 2022 $2,090,000 +$1,464,000 +234% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $9,225,000 +$8,663,000 +1541% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2022 $661,000 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q3 2021 $626,000 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $562,000 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2

Senti Biosciences, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,755,000 -$9,937,000 -85% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
2023 $11,692,000 -$3,870,000 -25% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
2022 $15,562,000 +$13,267,000 +578% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
2021 $2,295,000 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.